5 Reasons Intel's CEO Just Made This Stock Worth Buying

Intel shares have risen nearly 300% over the past year as CEO Lip-Bu Tan advances a multiyear turnaround, backed by a $10 million personal share purchase and approximately $20 billion equity raise at $95 per share. The company is developing its Crescent Island AI inference chip to avoid constrained high-bandwidth memory, while more than 1 million test wafers have run through its newest manufacturing tools and 14A process error rates are declining faster than expected. Support from the U.S. government, which owns just under 10% after a 433.3 million-share investment, and Nvidia's roughly $30 billion equity position strengthens turnaround credibility, though dilution prompted Bank of America and UBS to reduce price targets by about 4%-5%.

Analysis

The equity story has shifted from solvency/capex anxiety to execution optionality, but the rerating appears to have pulled forward a meaningful portion of the five-year recovery. A large equity raise improves runway yet makes per-share value creation substantially harder: incremental foundry and product gross-margin gains must exceed the cost of capital and offset dilution before EPS can inflect. The key near-term valuation variable is not strategic ownership or insider signaling; it is whether Intel can demonstrate external foundry customer commitments with economically attractive wafer pricing and credible yield progression.

A capacity-oriented inference accelerator could address the lower-cost serving market, but it should not be valued as a direct substitute for NVDA's training stack. The second-order beneficiary is commodity DRAM supply—MU, Samsung Electronics and SK Hynix—if designs genuinely substitute capacity-heavy conventional memory for scarce high-bandwidth memory; conversely, the design reinforces that HBM scarcity may persist for leading training systems. The risk is that inference buyers prioritize software compatibility, networking and total rack-level throughput over card availability, leaving a technically differentiated product without material attach rates.

Over the next 1-3 months, verify reported 14A defect-density/yield data, customer tape-outs, capex guidance and the accounting treatment of any government support before extrapolating manufacturing progress. Over 6-18 months, the decisive catalyst is gross-margin recovery alongside foundry losses narrowing; absent both, a higher revenue base can still destroy value through underutilized fabs. Any claimed strategic equity investment or government ownership should be independently reconciled to SEC filings, as the economics, lockups and governance rights determine whether it is durable capital or merely headline support.

Contrarian view: the market may be underestimating Intel's strategic value as a domestic advanced-packaging and leading-edge manufacturing alternative, but is likely overestimating the speed at which that value converts to free cash flow. A sustained premium multiple requires evidence that 14A can attract profitable external demand rather than simply reduce internal execution risk.

Key Decisions for Investors

• Do not chase INTC after the sharp rerating. Establish an alert—not a position—around the next earnings release for foundry operating loss, gross-margin trajectory, 14A customer commitments and capex; initiate only if management shows sequential margin improvement while maintaining external-customer milestones.
• Express the AI-memory bottleneck theme via a 3-6 month long MU position versus short SOXX only if server DRAM pricing and contract volumes continue rising; this captures potential inference-memory demand while reducing broad semiconductor-beta risk. Exit on evidence that inference deployments remain HBM-led or DRAM pricing rolls over.
• Maintain NVDA as the higher-quality AI exposure versus INTC on a 6-12 month horizon; Intel's inference offering is more likely to expand price-sensitive deployment tiers than displace NVIDIA's software-led training economics. Reassess if Intel reports material hyperscaler design wins with disclosed deployment timing.
• For a tactical INTC position, prefer defined-risk call spreads dated 6-9 months rather than common equity: upside requires verifiable execution catalysts, while dilution, weak utilization or a gross-margin guide-down could compress the multiple quickly. Falsify the bullish thesis on delayed 14A milestones, renewed capex escalation without customer prepayments, or another downward revision to foundry-loss guidance.